Compare Becton Dickinson and Co (BDX) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs GE Vernova Inc — how do they compare? Becton Dickinson and Co trades at $156.15 (market cap $41.51B), while GE Vernova Inc trades at $1,023.33 (market cap $286.46B). The key difference: GE Vernova Inc is far larger — about 6.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | GEV | |
|---|---|---|
Market Cap | $41.51B | $286.46B |
Sector | Health | Technology |
52-Week High | $185.39 | $1.17K |
52-Week Low | $135.49 | $547.96 |
Enterprise Value | $57.97B | $279.09B |
Dividend Yield | 2.79% | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
GE Vernova (GEV) trades at $1,042.60, down 4.49% today, amid mixed technical signals but strong fundamental momentum. The stock shows bullish moving averages and oversold RSI conditions, while recent earnings beats and a 23.81% net income margin highlight robust profitability. Analyst consensus remains strongly bullish with a $1,240 price target, supported by the company's $11 billion investment in grid reliability and nuclear energy expansion.
Outlook: GEV's leadership in AI power infrastructure and nuclear technology positions it for long-term growth, though high valuation multiples (P/E 31.15) and execution risks on capital investments warrant caution. Near-term catalysts include Q2 2026 earnings on July 22, 2026, and dividend payments in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
